Fluoroquinolone-resistant pneumococci: Dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2393-2399

  Domenech, Arnau ^a,b   Tirado Vélez, Jose M ^b,c   Fenoll, Asunción ^c   Ardanuy, Carmen ^a,b   Yuste, Jose ^b,c   Linãres, Josefina ^a,b   De La Campa, Adela G ^b,c,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; PNEUMOCOCCUS VACCINE; PROTEIN PARC; PROTEIN PARE; QUINOLONE DERIVATIVE;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLONE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL VACCINES; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 84896962408     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02669-13     Document Type: Article

References (42)

1. World Health Organization. 2007. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.
2. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746. http://dx.doi.org/10.1056/NEJMoa022823. (Pubitemid 36514704)
3. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:1455-1463. http://dx.doi.org/10.1056/NEJMoa051642.
4. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201:32-41. http://dx.doi.org/10.1086/ 648593.
5. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarragó D. 2009. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 47:1012-1020. http://dx.doi.org/10. 1128/JCM.01454-08.
6. Ardanuy C, Pallarés R, Calatayud L, Domínguez MA, Rolo D, Grau I, Martín R, Liñares J. 2009. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin. Infect. Dis. 48:57-64. http://dx.doi.org/10.1086/594125.
7. Moore MR, Gertz JRE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B. 2008. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197:1016-1027. http://dx.doi.org/10.1086/528996. (Pubitemid 351590031)
8. Drlica K, Zhao X. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392. (Pubitemid 28090230)
9. Muñoz R, de la Campa AG. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257. (Pubitemid 26328025)
10. Janoir C, Zeller V, Kitzis M-D, Moreau NJ, Gutmann L. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764. (Pubitemid 26404339)
11. Fernández-Moreira E, Balas D, González I, de la Campa AG. 2000. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb. Drug Resist. 6:259-267. http://dx.doi.org/10.1089/mdr.2000.6.259. (Pubitemid 32141461)
12. Tankovic J, Perichon B, Duval J, Courvalin P. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510. (Pubitemid 26367633)
13. Houssaye S, Gutmann L, Varon E. 2002. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:2712-2715. http://dx.doi.org/10. 1128/AAC.46.8.2712-2715.2002. (Pubitemid 34793495)
14. Chen DK, McGeer A, de Azavedo JC, Low DE. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239. http://dx.doi.org/10.1056/NEJM199907223410403.
15. The European Committee on Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0. http://www.eucast.org/clinical breakpoints/.
16. Fuller JD, Low DE. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121. http://dx.doi.org/10.1086/430829. (Pubitemid 40863754)
17. de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Pérez-Trallero E, Liñares J. 2004. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg. Infect. Dis. 10:1751-1759. http://dx.doi.org/10.3201/eid1010.040382. (Pubitemid 39319365)
18. de la Campa AG, Ardanuy C, Balsalobre L, Pérez-Trallero E, Marimón JM, Fenoll A, Liñares J. 2009. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg. Infect. Dis. 15:905-911. http://dx.doi.org/10.3201/ eid1506.080684.
19. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392. http://dx.doi.org/10.1128/AAC. 01617-06. (Pubitemid 351170804)
20. Riedel S, Beekmann SE, Heilmann KP, Richter SS, García-de-Lomas J, Ferech M, Goosens H, Doern GV. 2007. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 26:485-490. http://dx.doi.org/10.1007/s10096-007-0321-5. (Pubitemid 47025039)
21. Ip M, Chau SSL, Chi F, Cheuk ECS, Ma H, Lai RWM, Chan PK. 2007. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005. Antimicrob. Agents Chemother. 51:2192-2194. http://dx.doi.org/10.1128/AAC.00139-07. (Pubitemid 46903114)
22. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34:82-85. http://dx.doi.org/10.1016/j.ijantimicag.2009.02.002.
23. Fuller JD, McGeer A, Low DE. 2005. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur. J. Clin. Microbiol. Infect. Dis. 24:780-788. http://dx.doi.org/10.1007/s10096-005-0059-x. (Pubitemid 43042784)
24. Domenech A, Ardanuy C, Calatayud L, Santos S, Tubau F, Grau I, Verdaguer R, Dorca J, Pallares R, Martín R, Liñares J. 2011. Serotypes and genotypes of Streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. J. Antimicrob. Chemother. 66:487-493. http://dx.doi.org/10.1093/jac/dkq480.
25. Liñares J, de la Campa AG, Pallarés R. 1999. Fluoroquinolone resistance in Streptococcus pneumoniae. N. Engl. J. Med. 341:1546-1547. http://dx.doi.org/10.1056/NEJM199911113412013, 10.1056/NEJM199911113412012.
26. Rodríguez-Avial I, Ramos B, Rios E, Cercenado E, Ordobas M, Sanz JC. 2011. Clonal spread of levofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009. Antimicrob. Agents Chemother. 55:2469-2471. http://dx.doi.org/10.1128/AAC.01380-10.
27. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
28. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, Hakenbeck R, Hryniewicz W, Lefevre JC, Tomasz A, Klugman KP. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J. Clin. Microbiol. 39:2565-2571. http://dx.doi.org/10.1128/JCM.39.7.2565-2571.2001. (Pubitemid 32606233)
29. Enright MC, Spratt BG. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060. http://dx.doi.org/10.1099/ 00221287-144-11-3049. (Pubitemid 28515583)
30. González I, Georgiou M, Alcaide F, Balas D, Liñares J, de la Campa AG. 1998. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob. Agents Chemother. 42:2792-2798. (Pubitemid 28501205)
31. Balsalobre L, Ferrándiz MJ, Liñares J, Tubau F, de la Campa AG. 2003. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:2072-2081. http://dx.doi.org/10.1128/AAC.47.7.2072-2081.2003. (Pubitemid 36753553)
32. Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover FC. 2000. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2962-2968. http://dx.doi.org/10. 1128/AAC.44.11.2962-2968.2000.
33. Varon E, Janoir C, Kitzis M-D, Gutmann L. 1999. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:302-306.
34. Weigel LM, Anderson GJ, Facklam RR, Tenover FC. 2001. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:3517-3523. http://dx.doi.org/10.1128/AAC.45.12.3517-3523.2001. (Pubitemid 33107871)
35. Martín-Galiano AJ, de la Campa AG. 2003. High-efficiency generation of antibiotic-resistant strains of Streptococcus pneumoniae by PCR and transformation. Antimicrob. Agents Chemother. 47:1257-1261. http://dx.doi.org/10.1128/AAC.47.4.1257-1261.2003. (Pubitemid 36368582)
36. Patel SN, McGeer A, Melano R, Tyrrell GJ, Green K, Pillai DR, Low DE. 2011. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob. Agents Chemother. 55:3703-3708. http://dx.doi.org /10.1128/AAC.00237-11.
37. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797. http://dx.doi.org/10.1128/AAC.45.10.2793-2797. 2001. (Pubitemid 32906673)
38. Simoes AS, Pereira L, Nunes S, Brito-Avo A, de Lencastre H, Sa-Leao R. 2011. Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing pneumococci in the PCV7 era in Portugal. J. Clin. Microbiol. 49:2810-2817. http://dx.doi.org/10.1128/JCM.00517-11.
39. Grivea IN, Tsantouli AG, Michoula AN, Syrogiannopoulos GA. 2011. Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in central Greece. Vaccine 29:8882-8887. http://dx.doi.org/10.1016/j.vaccine.2011.09.074.
40. Domenech A, Ardanuy C, Tercero A, García-Somoza D, Santos S, Liñares J. 8 December 2013. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods. J. Antimicrob. Chemother. [Epub ahead of print.] http://dx.doi.org/10.1093/jac/dkt476.
41. Sanz JC, Cercenado E, Marín M, Ramos B, Ardanuy C, Rodríguez-Avial I, Bouza E. 2011. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV + patients. Clin. Microbiol. Infect. 17:1094-1098. http://dx.doi.org/10.1111/j.1469-0691.2011.03495.x.
42. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, García- García JJ, Pallarés R. 2008. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46:174-182. http://dx.doi.org/10.1086/524660. (Pubitemid 351269154)